• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regentis Biomaterials Ltd. Ordinary Shares (NY:RGNT)

2.000 -0.060 (-2.91%)
Official Closing Price Updated: 8:00 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regentis Biomaterials Ltd. Ordinary Shares

< Previous 1 2 Next >
MissionIRNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways
August 27, 2026
Via Investor Brand Network
Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC
August 27, 2026
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing
August 18, 2026
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market
August 14, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks
August 14, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
August 13, 2026
Via Investor Brand Network
Topics Intellectual Property
NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
August 07, 2026
Via Investor Brand Network
Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair
August 05, 2026
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair
July 31, 2026
Via Investor Brand Network
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets $3 Billion Cartilage Repair Market with Cell-Free Gelrin C
July 29, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones
July 28, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market
July 24, 2026
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology
July 20, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
July 20, 2026
From Regentis Biomaterials Ltd
Via ACCESS Newswire
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
July 15, 2026
Via Investor Brand Network
News headline image
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
July 15, 2026
From Regentis Biomaterials Ltd
Via ACCESS Newswire
The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics
July 07, 2026
Via Investor Brand Network
News headline image
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
June 17, 2026
From Regentis Biomaterials Ltd
Via ACCESS Newswire
News headline image
Sphere 3D Corp. (NASDAQ: ANY): Why Its 53MW Power Platform Is Drawing Attention Beyond Bitcoin Mining
June 10, 2026
Via AB Newswire
Topics Artificial Intelligence Economy
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC
June 08, 2026
Via Investor Brand Network
News headline image
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
June 08, 2026
Via ACCESS Newswire
News headline image
Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?
June 04, 2026
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones
May 29, 2026
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant
May 28, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Is ‘One to Watch’
May 27, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair
May 22, 2026
Via Investor Brand Network
News headline image
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
April 16, 2026
Via ACCESS Newswire
News headline image
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
March 17, 2026
Via ACCESS Newswire
News headline image
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
February 24, 2026
Via ACCESS Newswire
News headline image
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
February 19, 2026
Via ACCESS Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap